EvolusEOLS
EOLS logo
Fair Value
US$10
Share price02 Feb
US$6.9430.6% undervalued intrinsic discount
Loading
1Y-25.05%
7D0%

Cash Pay Aesthetics Exposure Will Test Injectable Demand Yet Long Term Potential Remains

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
02 Feb 26
Views
32
Not Invested

Fair Value vs Share Price

US$10
vs US$6.9430.6% undervalued intrinsic discount
PastFuture-137m446m2015201820212024202620272029Revenue US$445.5mEarnings US$93.2m
15.9%
Revenue growth
20.9%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Evolus

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with reasonable growth potential.

Market capUS$460.3m
PB-15.9x
Estimated Growth14.4%
Dividend YieldN/A
Full analysis

CEO & management

David Moatazedi
CEO
6.2yrs
CEO Tenure

A performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.